Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.71 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.62 |
| ▸ | VEGFA | P15692 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14328266 | 0.84 | HDAC8 (0.69) | HDAC8EGLN1VEGFAHDAC6IL1RN | |
| SCHEMBL14328169 | 0.84 | EGLN1 (0.71) | HDAC8EGLN1VEGFAHDAC6IL1RN | |
| SCHEMBL14328213 | 0.83 | HDAC8 (1.00) | HDAC8EGLN1VEGFAHDAC6 | |
| SCHEMBL14328176 | 0.82 | HDAC6 (0.75) | HDAC8EGLN1VEGFAHDAC6IL1RN | |
| SCHEMBL14322853 | 0.80 | HDAC8 (0.70) | HDAC8EGLN1VEGFAHDAC6IL1RN | |
| SCHEMBL12598859 | 0.79 | EGLN1 (0.73) | HDAC8EGLN1VEGFAHDAC6ALDH1A1 | |
| SCHEMBL14328173 | 0.78 | HDAC8 (0.73) | HDAC8EGLN1VEGFAHDAC6IL1RN | |
| SCHEMBL14328289 | 0.78 | HDAC8 (0.71) | HDAC8EGLN1VEGFAHDAC6IL1RN | |
| SCHEMBL1770401 | 0.77 | EGLN1 (1.00) | HDAC8EGLN1VEGFAHDAC6ALDH1A1 | |
| SCHEMBL1870351 | 0.77 | EGLN1 (0.76) | HDAC8EGLN1VEGFAHDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871728-B2 | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329741-A1 | NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF | HDAC5, HDAC3, HDAC1 | HDAC8 9/4885EGLN1 1258/4885VEGFA 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.